about
Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacologyThe recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's diseaseTargeting the dopamine D3 receptor: an overview of drug design strategies.Nurr1-Based Therapies for Parkinson's Disease.Pramipexole Increases Go Timeouts but Not No-go Errors in Healthy Volunteers.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.Dopaminergic Therapy Increases Go Timeouts in the Go/No-Go Task in Patients with Parkinson's Disease.
P2860
Q26738349-0C084E5B-C157-48FF-8540-8CC5C0F73AA9Q26745661-12077884-4E56-4A0F-915D-3E97F5BA1CEFQ34524556-069477CE-1387-4540-9981-F20C60CB60D4Q36803630-968E06C5-C286-4F93-B9CF-8BEE5A1FD8CFQ37345319-EB5DF442-680B-49A7-BBB6-FAA97B3A9CA3Q39324877-E32624EA-7946-46C4-B2B8-F5E241B9AA64Q47849289-7020BE54-97D3-476E-95ED-245A465CA0E8
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dopamine receptor agonists for Parkinson's disease.
@en
type
label
Dopamine receptor agonists for Parkinson's disease.
@en
prefLabel
Dopamine receptor agonists for Parkinson's disease.
@en
P2860
P1476
Dopamine receptor agonists for Parkinson's disease
@en
P2093
Marie-Therese Armentero
P2860
P304
P356
10.1517/13543784.2014.869209
P407
P577
2013-12-09T00:00:00Z